Medullary thyroid cancer (MTC) is a distinct and clinically significant thyroid malignancy that arises from the parafollicular C-cells rather than the follicular cells that give rise to the more common papillary and follicular thyroid cancers. Accounting for 3-5% of all thyroid cancers, MTC demands a fundamentally different treatment approach -- it does not respond to radioactive iodine, it frequently involves cervical lymph nodes requiring compartmental neck dissection, and approximately 25% of cases are hereditary, mandating genetic testing and family screening. At THANC Hospital in Chennai, Dr. Vidhyadharan Sivakumar performs medullary thyroid cancer surgery with the comprehensive approach this complex disease requires, integrating his MCh in Head & Neck Surgery, FEB-ORL HNS (European Board certification), FICRS, Gold Medal in MS (ENT), and over 3000 head and neck surgeries into a management pathway that encompasses surgery, genetic counseling, and lifelong surveillance.
Understanding Medullary Thyroid Cancer
The thyroid gland contains two distinct cell populations. The follicular cells produce thyroid hormones (T3 and T4) and are the origin of papillary and follicular thyroid cancers. The parafollicular C-cells, concentrated in the upper poles, produce calcitonin -- a hormone involved in calcium metabolism. Medullary thyroid cancer arises from these C-cells, which explains its fundamentally different biology and treatment requirements.
MTC accounts for approximately 3-5% of thyroid cancers worldwide. Despite its relative rarity, it is responsible for a disproportionate share of thyroid cancer-related deaths because of its more aggressive behaviour and its insensitivity to radioactive iodine. In India, the actual incidence is likely underreported due to the specialised diagnostic workup required, including serum calcitonin measurement that is not routinely performed for all thyroid nodules.
The most clinically significant feature of MTC is its hereditary component. Approximately 25% of all cases are caused by germline mutations in the RET proto-oncogene. Every MTC diagnosis therefore carries implications beyond the individual patient -- it may signal a familial cancer syndrome affecting multiple family members across generations. Understanding the complete landscape of thyroid cancer surgery helps patients appreciate how MTC treatment differs from the more common differentiated thyroid cancers.
Calcitonin serves as a remarkably sensitive and specific tumour marker for MTC. It can detect MTC before it becomes clinically apparent, guide surgical planning, and monitor for recurrence after treatment.
Types and Classification
Medullary thyroid cancer is classified into distinct forms based on its genetic basis, each with different clinical implications:
Sporadic MTC accounts for approximately 75% of all cases. It occurs without a family history, typically presents as a unilateral thyroid nodule in patients aged 40-60, and is usually unifocal. Somatic RET mutations within the tumour are found in 40-65% of sporadic cases.
Hereditary MTC accounts for 25% of cases and occurs as part of three recognised syndromes:
| Syndrome | Components | Common RET Mutations | Typical MTC Onset | Aggressiveness |
|---|---|---|---|---|
| MEN2A | MTC + pheochromocytoma (50%) + hyperparathyroidism (20-30%) | Codons 634, 609, 611, 618, 620 | Childhood to young adult | Moderate |
| MEN2B | MTC + pheochromocytoma (50%) + mucosal neuromas + marfanoid habitus | Codon 918 (M918T) | Infancy/early childhood | Most aggressive |
| Familial MTC (FMTC) | MTC only (no other endocrine tumours) | Various RET codons | Adulthood | Least aggressive |
MEN2A is the most common hereditary form. MEN2B is the rarest but most aggressive -- MTC can develop in infancy with early metastases. Every patient diagnosed with MTC -- regardless of family history -- must undergo RET germline genetic testing. Approximately 1-7% of apparently sporadic cases harbour germline RET mutations, reclassifying them as hereditary and triggering family screening.
Causes and Risk Factors
Unlike papillary and follicular thyroid cancers, MTC is not associated with radiation exposure or iodine deficiency -- reflecting its different cell of origin.
- RET germline mutations: The primary risk factor. Specific mutations correlate with aggressiveness and age of onset, enabling risk-stratified prophylactic surgery.
- RET somatic mutations: Found in 40-65% of sporadic tumours; may guide targeted therapy selection.
- Family history: Any first-degree relative with MTC, pheochromocytoma, or hyperparathyroidism should trigger MEN2 evaluation.
- C-cell hyperplasia: This precancerous increase in C-cell numbers can progress to MTC -- the rationale for prophylactic thyroidectomy in RET carriers.
- Age and sex: Sporadic MTC peaks in the 5th-6th decade. Hereditary MTC affects both sexes equally and presents earlier.
Signs and Symptoms
Medullary thyroid cancer may present with a range of symptoms, some unique to this cancer type:
- Thyroid nodule: A firm, palpable nodule, often in the upper pole of the thyroid where C-cells are concentrated. Hereditary MTC frequently presents with bilateral nodules.
- Cervical lymphadenopathy: Palpable neck lymph nodes are present in 50-70% of patients at diagnosis, reflecting MTC's high rate of nodal metastasis.
- Diarrhoea: Secretory diarrhoea caused by elevated calcitonin and other peptides is a characteristic symptom of MTC, occurring in 10-30% of patients, particularly those with advanced disease.
- Facial flushing: Episodic flushing may accompany elevated calcitonin levels or coexisting pheochromocytoma.
- Cushing syndrome: Rare ectopic ACTH production by MTC can cause Cushing syndrome.
- MEN2B features: Mucosal neuromas (bumps on the tongue, lips, and eyelids), marfanoid body habitus, and intestinal ganglioneuromatosis may precede the MTC diagnosis.
- Pheochromocytoma symptoms: Episodic hypertension, headaches, palpitations, and sweating in MEN2A/2B patients.
Any thyroid nodule accompanied by unexplained diarrhoea, flushing, or a family history of thyroid cancer or pheochromocytoma should raise immediate suspicion for MTC and prompt serum calcitonin measurement.
Diagnosis at THANC Hospital
Dr. Vidhyadharan follows a comprehensive, protocol-driven diagnostic pathway for suspected medullary thyroid cancer at THANC Hospital, reflecting the specialised workup this disease demands.
Serum calcitonin and CEA is the critical first step. Calcitonin above 100 pg/mL is virtually diagnostic of MTC. CEA is a complementary marker -- rapidly rising CEA with stable calcitonin suggests dedifferentiation. Both serve as preoperative baselines.
Neck ultrasound characterises the nodule and maps lymph node compartments. MTC nodules are typically solid, hypoechoic, with coarse calcifications. Lymph node mapping of central and lateral compartments directly influences surgical extent.
FNAC with calcitonin washout confirms the diagnosis. MTC cells show characteristic spindle-shaped or plasmacytoid morphology with amyloid deposits. Calcitonin measurement in the needle washout improves accuracy for both primary tumour and lymph nodes.
RET genetic testing is mandatory for every MTC patient, screening for germline mutations that guide family screening and prophylactic surgery timing.
Pheochromocytoma screening with plasma metanephrines is essential before surgery -- an undiagnosed pheochromocytoma can trigger life-threatening hypertensive crisis.
Cross-sectional imaging (CT neck/chest, liver MRI, bone scan or PET-CT) is performed when calcitonin exceeds 500 pg/mL. Calcium and PTH are checked to screen for hyperparathyroidism in suspected MEN2A.
How Dr. Vidhyadharan Treats Medullary Thyroid Cancer
At THANC Hospital, Dr. Vidhyadharan performs medullary thyroid cancer surgery with the comprehensive compartmental approach that MTC demands. His MCh in Head & Neck Surgery provides the specialised training essential for the extensive neck dissection that is standard in MTC treatment, and his routine use of IONM ensures nerve preservation during these technically demanding bilateral procedures.
Total Thyroidectomy: Always Required
Unlike papillary thyroid cancer where lobectomy may be appropriate for low-risk disease, medullary thyroid cancer always requires total thyroidectomy. C-cells are distributed throughout both thyroid lobes, and hereditary MTC is frequently bilateral and multifocal. Even apparently sporadic unilateral MTC requires total thyroidectomy because occult C-cell hyperplasia or microscopic MTC may be present in the contralateral lobe. There is no role for lobectomy alone in confirmed MTC.
Compartmental Neck Dissection: The Oncological Standard
The high rate of lymph node metastasis in MTC (50-70% at presentation) mandates systematic compartmental neck dissection. Dr. Vidhyadharan performs compartment-oriented dissection -- removing all fibroadipose tissue containing lymph nodes within the targeted compartments -- rather than selectively removing individual nodes.
Bilateral central neck dissection (Level VI) is performed in every MTC surgery, from the hyoid bone superiorly to the innominate artery inferiorly, between both carotid arteries. This compartment harbours the nodes most frequently involved by MTC. IONM is critical during this dissection given the proximity of both recurrent laryngeal nerves and all four parathyroid glands.
Lateral neck dissection (Levels II-V) is added when preoperative imaging detects lateral lymph node metastases or when calcitonin levels suggest significant disease burden:
| Preoperative Calcitonin (pg/mL) | Likely Disease Extent | Recommended Surgical Extent |
|---|---|---|
| 20-200 | Intrathyroidal or limited central nodal disease | Total thyroidectomy + bilateral central neck dissection |
| 200-500 | Ipsilateral lateral nodal disease likely | Add ipsilateral lateral neck dissection |
| >500 | Bilateral lateral and possible distant disease | Add bilateral lateral neck dissection; stage for distant metastases |
IONM Nerve Monitoring
The extensive bilateral dissection required for MTC places both recurrent laryngeal nerves at particular risk. Dr. Vidhyadharan uses IONM throughout every MTC surgery at THANC Hospital to identify, map, and confirm nerve function at each stage of the operation. This is especially critical during bilateral central neck dissection where both nerves are exposed simultaneously.
Prophylactic Thyroidectomy in RET Mutation Carriers
When RET genetic testing identifies a pathogenic mutation in a family member who has not yet developed MTC, prophylactic thyroidectomy can prevent cancer entirely -- one of the most powerful examples of precision medicine:
- Highest risk (MEN2B, codon 918): Thyroidectomy within the first 6 months of life
- High risk (codon 634, A883F): Thyroidectomy by age 5 years
- Moderate risk (other RET mutations): Thyroidectomy in early adulthood, or active surveillance with annual calcitonin and ultrasound, with surgery when calcitonin rises or structural abnormalities appear
The extent of prophylactic surgery (thyroidectomy alone versus thyroidectomy with central neck dissection) depends on the patient's age, calcitonin level, and ultrasound findings.
Pheochromocytoma-First Protocol
In MEN2 patients with concurrent pheochromocytoma, the adrenal tumour must be resected before thyroidectomy to prevent life-threatening hypertensive crisis. Dr. Vidhyadharan coordinates with endocrine surgeons at THANC Hospital to ensure correct sequencing.
Targeted Therapy for Advanced MTC
For unresectable or metastatic MTC, targeted therapies have transformed management. Selpercatinib and pralsetinib are highly selective RET inhibitors with 60-70% response rates. Vandetanib and cabozantinib are multikinase inhibitors approved for progressive MTC. These are coordinated with the medical oncology team at THANC Hospital.
What to Expect: Your Treatment Journey
The treatment journey for medullary thyroid cancer at THANC Hospital is more comprehensive than for differentiated thyroid cancers, reflecting the unique complexities of MTC management.
Week 1 -- Initial evaluation: Clinical examination, neck ultrasound, flexible laryngoscopy. Blood tests include calcitonin, CEA, RET genetic testing, plasma metanephrines, calcium, PTH, and thyroid function. FNAC with calcitonin immunostaining is performed on the nodule and suspicious lymph nodes.
Week 2-3 -- Results and surgical planning: Once RET genetic results (2-3 weeks) and other investigations are available, Dr. Vidhyadharan discusses the complete picture: diagnosis, genetic status, pheochromocytoma status, and planned surgical extent. For hereditary cases, genetic counseling is offered to family members. Understanding the financial aspects of thyroid surgery in Chennai helps patients plan for the comprehensive treatment MTC requires.
Surgery day: Total thyroidectomy with bilateral central neck dissection (and lateral dissection if indicated) under general anaesthesia with continuous IONM. Duration typically 3-5 hours. A drain is placed and removed within 1-3 days.
Post-surgery (2-4 days): Calcium monitored every 6-12 hours. Levothyroxine started at replacement dose. Calcitonin and CEA measured at 2-3 months to determine biochemical cure.
Long-term follow-up: Calcitonin and CEA every 3-6 months for 2 years, then every 6-12 months. Neck ultrasound every 6-12 months. Cross-sectional imaging guided by calcitonin levels.
Recovery and Rehabilitation
Recovery after medullary thyroid cancer surgery is influenced by the extent of dissection performed, which is typically more extensive than for differentiated thyroid cancers.
Hospital stay is typically 2-4 days -- longer than for simple thyroidectomy because of the bilateral neck dissection and closer calcium monitoring required.
Calcium management is particularly important. The bilateral central neck dissection places all four parathyroid glands at risk. Temporary hypoparathyroidism occurs in 15-30% of patients. Dr. Vidhyadharan meticulously preserves parathyroid glands and their blood supply, autotransplanting devascularised glands when necessary. Calcium and vitamin D supplementation are adjusted based on laboratory levels. Permanent hypoparathyroidism occurs in fewer than 3-5%.
Thyroid hormone replacement with levothyroxine is started immediately after surgery at replacement doses to achieve a normal TSH. Unlike differentiated thyroid cancers, TSH suppression provides no benefit in MTC because C-cells are not TSH-responsive.
Voice and swallowing are assessed postoperatively. The bilateral dissection near both recurrent laryngeal nerves makes IONM especially critical for MTC surgery. Any voice changes are evaluated with laryngoscopy and managed with speech therapy if required.
Return to activities occurs within 2-4 weeks for most patients, with full recovery by 6 weeks. Patients who undergo lateral neck dissection may experience temporary shoulder stiffness, managed with physiotherapy.
Outcomes and Prognosis
Medullary thyroid cancer prognosis is primarily determined by the extent of disease at initial surgery and whether biochemical cure (normalisation of calcitonin) is achieved:
- Localised MTC (confined to thyroid, no lymph nodes): 10-year survival exceeds 95%. Biochemical cure rate approximately 80-90%.
- MTC with central lymph node metastases: 10-year survival approximately 75%. Biochemical cure rate approximately 50-60%.
- MTC with lateral lymph node metastases: 10-year survival approximately 60-70%. Biochemical cure rate approximately 20-30%.
- Distant metastatic MTC: 10-year survival approximately 40%. Biochemical cure rarely achieved, but prolonged disease control is possible with targeted therapies.
The single most important prognostic factor is the completeness of the initial surgery. Calcitonin doubling time is the strongest predictor of outcome in persistent disease -- exceeding 2 years indicates indolent disease, while under 6 months indicates aggressive disease requiring systemic therapy.
Why Choose Dr. Vidhyadharan at THANC Hospital
Medullary thyroid cancer is one of the most technically and clinically complex thyroid malignancies. It demands a surgeon with specific expertise in comprehensive compartmental neck dissection, genetic cancer syndrome management, and multidisciplinary coordination. Dr. Vidhyadharan Sivakumar offers:
- MCh (Head & Neck Surgery) from Amrita Institute -- super-speciality training that specifically covers compartmental neck dissection and complex thyroid surgery including MTC.
- FEB-ORL HNS (European Board certification) -- the highest European standard of head and neck surgical qualification, reflecting rigorous evidence-based training.
- Gold Medal in MS (ENT) from Annamalai University -- demonstrating foundational excellence in surgical anatomy.
- FICRS and training across 8 countries -- including microsurgery at Chang Gung Memorial Hospital Taiwan, skull base surgery at Toronto General Hospital Canada, and the ASOHNS fellowship at Royal Adelaide Hospital Australia.
- Over 3000 head and neck surgeries -- providing the operative experience essential for the extensive bilateral dissection MTC requires.
- Routine IONM nerve monitoring -- critical during bilateral central and lateral neck dissection.
- Integrated genetic counseling pathway -- RET genetic testing and family screening coordinated as part of every MTC management plan.
- Multidisciplinary tumour board at THANC Hospital with medical oncology, nuclear medicine, endocrinology, genetics, and pathology.
For a personalised assessment and treatment plan, schedule a consultation with Dr. Vidhyadharan Sivakumar at THANC Hospital, Kilpauk, Chennai.
Phone: +91 73059 53378 Location: THANC Hospital, 747 Poonamallee High Road, Kilpauk, Chennai 600010 Book an Appointment
